- Is Advancing Cancer Treatment a tax-exempt 501(c)(3)?
- Yes. Advancing Cancer Treatment is recognised by the IRS as a 501(c)(3) organisation (EIN 83-2886283). The IRS recognised Advancing Cancer Treatment as tax-exempt in February 2019.
- What is Advancing Cancer Treatment's EIN?
- Advancing Cancer Treatment's Employer Identification Number (EIN) is 83-2886283. The EIN was assigned by the IRS in February 2019. Donors and grantmakers use the EIN to verify tax-exempt status with the IRS.
- What does Advancing Cancer Treatment do?
- Acts mission is to make the Washington, DC metropolitan area a leader in Advancing clinical trial accrual, thus accelerating improved Cancer care and Treatment.
- Where is Advancing Cancer Treatment located?
- Advancing Cancer Treatment is located at 42 Ruppert RD, Moultonborough, NH, 03254.
- When was Advancing Cancer Treatment founded or recognised by the IRS?
- Advancing Cancer Treatment was recognised by the IRS as a tax-exempt organisation in February 2019. The IRS ruling date is the earliest authoritative date available for most US nonprofits.
- What is Advancing Cancer Treatment's annual revenue?
- On its most recent Form 990 (fiscal year 2024), Advancing Cancer Treatment reported $43K in total revenue and $824K in total expenses.
- Has Advancing Cancer Treatment been auto-revoked by the IRS?
- No. Advancing Cancer Treatment (EIN 83-2886283) does not appear on the IRS Auto-Revocation List. Givalgo Discover cross-references the IRS Auto-Revocation List on every profile load; if status changes, this page reflects it.
- Is Advancing Cancer Treatment listed in IRS Publication 78?
- Yes. Advancing Cancer Treatment is listed in IRS Publication 78 as an organisation eligible to receive tax-deductible charitable contributions. Pub 78 status is the canonical IRS signal that donations to an org are deductible.
